Pharmacokinetics and bactericidal rates of daptomycin and vancomycin in intravenous drug abusers being treated for gram-positive endocarditis and bacteremia
- PMID: 1324637
- PMCID: PMC188844
- DOI: 10.1128/AAC.36.5.1109
Pharmacokinetics and bactericidal rates of daptomycin and vancomycin in intravenous drug abusers being treated for gram-positive endocarditis and bacteremia
Abstract
The pharmacokinetics and bactericidal killing rates (BR) of daptomycin (D) and vancomycin (V) in 12 intravenous drug abusers (6 treated with daptomycin and 6 treated with vancomycin) were evaluated. Pharmacokinetic parameters were determined from multiple serum samples drawn at steady state over a 12-h dosing interval after intravenous infusions of 3 mg of D per kg of body weight and 1,000 mg of V. The BRs were determined from the 1- and 6-h serum samples by using four isolates of Staphylococcus aureus (three methicillin susceptible and one methicillin resistant) obtained from the patients enrolled in the study. Peak serum daptomycin concentrations were lower and volumes of distribution were higher than reported in healthy volunteers. Although not statistically different, D clearance was 22% higher than reported in healthy volunteers. V pharmacokinetics were similar to those reported in previous studies. Daptomycin's BRs, although comparable to those of V in patients' serum, were significantly decreased compared with those found in broth. This may be related to the high degree of protein binding of D (93% versus 50% for V). Conversely, the BRs of V in serum were significantly greater than those in broth. The BRs of D and V in broth were greater when killing curves were performed with test strains in logarithmic versus stationary-phase growth. The ability to kill organisms in stationary phase may be an important factor in determining the performance of an antibiotic in deep-seated infections such as endocarditis.3+
Similar articles
-
In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin.Antimicrob Agents Chemother. 1992 Dec;36(12):2709-14. doi: 10.1128/AAC.36.12.2709. Antimicrob Agents Chemother. 1992. PMID: 1336344 Free PMC article.
-
Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations.Antimicrob Agents Chemother. 2005 Jul;49(7):2735-45. doi: 10.1128/AAC.49.7.2735-2745.2005. Antimicrob Agents Chemother. 2005. PMID: 15980344 Free PMC article.
-
Comparative efficacy of daptomycin, vancomycin, and cloxacillin for the treatment of Staphylococcus aureus endocarditis in rats and role of test conditions in this determination.Antimicrob Agents Chemother. 1990 Dec;34(12):2348-53. doi: 10.1128/AAC.34.12.2348. Antimicrob Agents Chemother. 1990. PMID: 1965105 Free PMC article.
-
Clinical experience with daptomycin: bacteraemia and endocarditis.J Antimicrob Chemother. 2008 Nov;62 Suppl 3:iii35-39. doi: 10.1093/jac/dkn369. J Antimicrob Chemother. 2008. PMID: 18829724 Review.
-
Bacteremia due to Methicillin-Resistant Staphylococcus aureus: New Therapeutic Approaches.Infect Dis Clin North Am. 2016 Jun;30(2):491-507. doi: 10.1016/j.idc.2016.02.009. Infect Dis Clin North Am. 2016. PMID: 27208769 Review.
Cited by
-
Activity of serum concentrations of daptomycin vs. vancomycin against vancomycin-susceptible and resistant Enterococcus faecium in the presence of albumin physiological concentrations: an in vitro pharmacodynamic simulation.Eur J Clin Microbiol Infect Dis. 2008 Oct;27(10):1009-11. doi: 10.1007/s10096-008-0525-3. Epub 2008 May 21. Eur J Clin Microbiol Infect Dis. 2008. PMID: 18493805 No abstract available.
-
Teicoplanin and daptomycin bactericidal activities in the presence of albumin or serum under controlled conditions of pH and ionized calcium.Antimicrob Agents Chemother. 1993 Mar;37(3):605-9. doi: 10.1128/AAC.37.3.605. Antimicrob Agents Chemother. 1993. PMID: 8384822 Free PMC article.
-
Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections.Antimicrob Agents Chemother. 1996 Mar;40(3):696-700. doi: 10.1128/AAC.40.3.696. Antimicrob Agents Chemother. 1996. PMID: 8851595 Free PMC article. Clinical Trial.
-
Optimizing Antibiotic Therapy for Intravenous Drug Users: A Narrative Review Unraveling Pharmacokinetics/Pharmacodynamics Challenges.Eur J Drug Metab Pharmacokinet. 2024 Mar;49(2):123-129. doi: 10.1007/s13318-024-00882-8. Epub 2024 Feb 8. Eur J Drug Metab Pharmacokinet. 2024. PMID: 38332425 Review.
-
Once-daily dosing in dogs optimizes daptomycin safety.Antimicrob Agents Chemother. 2000 Nov;44(11):2948-53. doi: 10.1128/AAC.44.11.2948-2953.2000. Antimicrob Agents Chemother. 2000. PMID: 11036005 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources